ZURICH/BERLIN, May 6 (Reuters) - The Swiss blue-chip SMI was seen opening down 1.7 percent at 9,577 points on Monday, according to premarket indications by bank Julius Baer . Here are some of the main factors that may affect Swiss stocks:
The drugmaker's gene therapy unit Avexis said new data showed positive results of its Zolgensma drug for a broad spectrum of spinal muscular atrophy patients.
The company is confident it will complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics despite running into delays from U.S authorities reviewing the deal, the head of the Swiss company's pharma division told Finanz und Wirtschaft.
Separately, U.S. regulator FDA approved Kadcyla, a drug by Roche's Genetech unit, for a specific treatment of breast cancer. [bit.ly/2UYWOVN ]
*Datacolor AG said it reached sales of $39.7 million in the first half of its fiscal year.
* Landis + Gyr said it expected 2019 group adjusted EBITDA to be between $240 to $255 million after reporting a 14.3 percent rise to $237.9 million for 2018.
* Leclanche proposed Lluis Farga Mas to be elected as a new independent member for its board of directors.
ABB- 0.80 CHF/shr dividend
Reporting by Zurich newsroom and Berlin Speed Desk